When the human prostate cancer cell line, LNCaP 104-S, the growth of which is stimulated by physiological levels of androgen, is cultured in androgen-depleted medium for >100 and androgen-independent LNCaP 104-R2t sublines were isolated as described (6). The characteristics of these cells in vitro were confirmed before injection into nude mice. Briefly, proliferation of LNCaP 104-S cells increased 10-to 13-fold in medium containing charcoal-treated fetal bovine serum (FBS) and 0.1 nM synthetic androgen R1881, compared with cells cultured in medium containing charcoal-treated FBS without added androgen. LNCaP 104-R2 cells grew in medium supplemented with charcoal-treated FBS without additional androgen. Their proliferation was not stimulated but was repressed by 0.1 nM R1881. LNCaP 104-S cells were maintained in DMEM (GIBCO) supplemented with 1 nM S5t-dihydrotestosterone and 10% FBS (Summit Biotechnology, Ft. Collins, CO), and LNCaP 104-R2 cells were maintained in DMEM supplemented with 10% FBS treated with charcoal to remove steroid (6). PC-3 and MCF-7 cell lines were obtained from the American Type Culture Collection (Rockville, MD) and were maintained in DMEM supplemented with 10% FBS.
one acetate, also inhibited LNCaP 104-R2 tumor growth. Removal of TP or implantation of finasteride, a 5a-reductase inhibitor, in nude mice bearing TP implants resulted in the regrowth of LNCaP 104-R2 tumors. Within 1 week after TP implantation, LNCaP 104-R2 tumors exhibited massive necrosis with severe hemorrhage. Three weeks later, these tumors showed fibrosis with infiltration of chronic inflammatory cells and scattered carcinoma cells exhibiting degeneration. TP treatment of mice with LNCaP 104-R2 tumors reduced tumor androgen receptor and c-myc mRNA levels but increased prostate-specific antigen in serum-and prostatespecific antigen mRNA in tumors. Although androgen ablation has been the standard treatment for metastatic prostate cancer for >50 years, our study shows that androgen supplementation therapy may be beneficial for treatment of certain types of human prostate cancer and that the use of 5a-reductase inhibitors, such as finasteride or anti-androgens, in the general treatment of metastatic prostate cancer may require careful assessment.
Prostate cancer is now the most commonly diagnosed cancer in American men. In 1996, 317,100 new prostate cancer cases are expected and 41,400 men may die from prostate cancer (1) . The growth and development of prostate cancer is initially androgen-dependent, and androgen ablation therapies have been the standard treatment for metastatic prostate cancer since Charles Huggins published his classic report in 1941 (2) . Prostate cancer patients treated with androgen ablation therapy often have remission of their prostate cancer, but within a few years, tumor regrowth occurs. The recurrence of prostate cancer is largely due to progression of initially androgendependent prostate cancer cells to tumor cells that do not depend on androgen for their proliferation (3) (4) (5) . The reason for this loss of androgen dependency is not known, but human prostate cancer cells, including various LNCaP sublines, have been used to study the changes occurring during progression and tumorigenesis (6) (7) (8) (9) . Some androgen-independent prostate cancer cell lines, such as PC-3 and DU-145, lack androgen receptor (AR; ref. 10). However, AR has been found in metastatic prostate cancer after ablation therapy (11) , and progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors (12) .
To mimic the natural course of human prostate cancer, we have derived LNCaP 104-R2 cells from the androgendependent LNCaP 104-S cells, after long-term culture in androgen-depleted medium (6) . LNCaP 104-R2 cells contain AR, but their proliferation is not dependent on androgen. Instead, these cells are proliferatively repressed by very low concentrations of androgen in culture medium. We report here that testosterone prevents and suppresses the growth of LNCaP 104-R2 tumors in nude mice and that this effect was inhibited by finasteride, a 5ax-reductase inhibitor.t
MATERIALS AND METHODS
Cell Lines. Androgen-dependent LNCaP 104-S (passage 37) and androgen-independent LNCaP 104-R2t sublines were isolated as described (6) . The characteristics of these cells in vitro were confirmed before injection into nude mice. Briefly, proliferation of LNCaP 104-S cells increased 10-to 13- RNA Analysis. Total RNA was isolated from tumor tissue using the acid-guanidium thiocyanate phenol-chloroform extraction method (14) . Ribonuclease protection assay (15, 16) was performed using probes generated from a 210-bp KpnISacl fragment of human AR cDNA (6, 17) , a 77-bp fragment of human PSA cDNA (6, 18) , a 252-bp PstI-ClaI fragment of human c-myc cDNA (19) , and a 144-bp PstI-HincII fragment at the 5' terminus of human 2 microglobulin (20 (-) and the other without implants served as controls (0). Mice treated with TP starting at week 4 had small tumors (88 ± 13 mm3) and were divided into three groups: mice with TP implanted initially at the 4th week (see Fig. 1 ) and no additional treatment (-), mice implanted with TP at the 4th week and implanted with finasteride (FS) at the 7th week (A), and mice implanted with TP at the 4th week and removal of implanted TP at the 7th week (D). Tumor size was measured every week. Each point represents data for five tumors. resulted in a rapid reduction in tumor size. The effect of TP was clearly visible within 1 week; massive hemorrhage was seen in tumors (Fig. 4B) . Four weeks after TP implantation, tumor size was reduced to 208 + 33 mm3 (Figs. 3 and 4C) . If TP was removed at the 7th week from LNCaP 104-R2 tumor-bearing mice that were originally implanted with TP at the 4th week (Fig. 1) (Fig. 6B) . At the 4th week after TP treatment, tumor size was markedly decreased, and histological sections revealed fibrosis with infiltration of chronic inflammatory cells and scattered carcinoma cells in the process of degeneration (Fig. 6C) .
Effect ofAndrogen on the Expression of AR, c-myc, and PSA by LNCaP 104-R2 Tumors. Immunocytochemical staining of LNCaP 104-R2 tumors localized AR to the nucleus (Fig. 6D) and PSA to the cytoplasm (Fig. 6E ) in tumor cells but not in surrounding mouse cells. The level of mRNA for AR and c-myc in the LNCaP 104-R2 tumor was reduced by 50% to 70% within 3 days after TP implantation (Fig. 7) . This initial rapid loss preceded the general loss of tumor cells. The level of PSA mRNA in tumor samples (Fig. 7) 
DISCUSSION
Androgens are necessary for normal prostate development and function. Most newly diagnosed prostate cancers are also androgen-dependent. However, the human prostate cancer lines, LNCaP 104-Ri (9) and 104-R2 cellst, which contain a very high level of AR (over 10-fold that of androgenstimulatory LNCaP 104-S cells), are not proliferatively stimulated by androgen but are actually repressed by low concentrations (0.1 nM) of androgens. It has been reported that the proliferation of PC-3 cells transfected with an AR expression vector also is inhibited by androgen in culture (27) . We also have found that PC-3 cells retrovirally infected with an AR expression vector do not survive well in culture.
The molecular mechanism involved in androgen-dependent suppression of prostate tumor cell growth is not clear. Since of an appropriate concentration of androgen (30) . Androgen also suppresses the expression of prostatic sulfated glycoprotein-2 (clusterin; refs. 31 and 32), which prevents LNCaP cell death induced by tumor necrosis factor a (33) . Tumor growth is dependent on tumor angiogenesis (34 The 5a-reductase inhibitor finasteride has been found to be effective in the treatment of benign prostatic hyperplasia in some patients (36) . Finasteride is also being tested for the chemoprevention of prostate cancer (37 (40) . The effect of androgen therapy on metastatic cancer of the prostate in a limited number of patients has been reported (41) . Although no objective evidence of tumor remission was found, a limited number of patients experienced relief of symptoms. Optimization of dosage and better patient selection (long-term androgen ablation without adjuvant therapies) may be needed to enhance the therapeutic results of androgen therapy.
